the invention relates to derivatives of (i) pyridino - pyridinones according to formula (i): in which r1 is a hydrogen atom, or an alkyl (c1-c4) group； r2 is a group - (ch2) n (where n = 0, 1, 2, 3, or 4, and b represents a group (c3 - c5 cycloalkyl group). (c1 - c4) alkyl or a (c1-c4) alkoxy group, y, z, v and w areindependently of each other in a group - ch -, a carbon atom, an atom or atoms, on the understanding that the cycle, in which v, w, y, and z are included, is a cycle of five or six members, on the understanding that the dotted line in the ring cycle indicates that the resulting is an aromatic ring and the understanding that the cycle includes a.1 or 2 heteroatoms； r3 and r4 are independently of one another, identical or different, is selected from a hydrogen atom and an alkyl group (c1 - c4) are linear or together with the carbon to which they are related to a group (c3-c5) cycloalkyl； m is a number all equal to 1.3 or 4； and r5 represents a hydrogen atom or an alkyl (c1-c4) group； r6 is a group - (ch2) n -, where n = 0, 1, 2 or 3, and l is a group selected from among the six carbon atoms, aryl, h u00e9t u00e9roaryles 5 or 6 the saturated heterocycles containing links 5, 6 or seven membered or formed together with the nitrogen atom to which they are linked to a heterocyclic group.(ii) and (iii) the preparation and their application in therapy as inhibitors of the kinase activity of receptors to ligands pdgfs and / or flt3 ligand receptors.L'invention se rapporte (i) à des dérivés de pyridino-pyridinones répondant à la formule (I) : dans laquelle, R1 représente un atome d'hydrogène ou un groupe (C1 -C4)alkyle； R2 représente un groupement -(CH2)n-B où n'=0, 1, 2, 3 ou 4 et B représente un groupe (C3-C5)cycloalkyle, un groupe (C1 -C4)alkyle ou un groupe (C1 -C4)alcoxy； Y, Z, V et W représentent, indépendamment les uns des autres un groupe -CH-, un atome de carbone, un hétéroatome ou pas d'atome, étant entendu que le cycle, dans lequel V, W, Y et Z sont com
